Compare BCBP & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | CVRX |
|---|---|---|
| Founded | 2000 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.1M | 160.8M |
| IPO Year | 2005 | 2021 |
| Metric | BCBP | CVRX |
|---|---|---|
| Price | $11.28 | $5.38 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $10.00 | ★ $10.50 |
| AVG Volume (30 Days) | 101.7K | ★ 361.6K |
| Earning Date | 04-21-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | ★ $56,651,000.00 |
| Revenue This Year | $85.26 | $17.17 |
| Revenue Next Year | $6.14 | $17.69 |
| P/E Ratio | $43.58 | ★ N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $7.31 | $4.37 |
| 52 Week High | $11.71 | $11.30 |
| Indicator | BCBP | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 69.54 | 36.94 |
| Support Level | $7.55 | $5.06 |
| Resistance Level | N/A | $8.10 |
| Average True Range (ATR) | 0.30 | 0.40 |
| MACD | 0.13 | 0.02 |
| Stochastic Oscillator | 80.00 | 6.25 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.